Preimplantation Genetic Diagnosis May Pose Neurological Risks
By Medical News Today,
Medical News Today
| 07. 23. 2009
Preimplantation genetic diagnosis (PGD) has helped many couples conceive healthy children and is generally considered a safe practice. However, a new long-term analysis of PGD in mice suggests that this procedure may increase risks of weight gain and memory decline in adulthood.
PGD is used alongside assisted reproduction technologies to ensure couples that may be carriers of genetic disease (e.g. Ashkenazi Jews who have a high incidence of Tay-Sachs among their population) don't pass on defective genes to their children. While PGD is not believed to pose any serious health risks, the procedure does involve manipulating the developing embryo and no rigorous long-term studies have been carried out.
Ran Huo, Qi Zhou and colleagues used a mouse model to examine how a blastomere biopsy, as the key manipulation during the PGD procedure, could affect fetal, neonatal and adult development.
They found that there were no differences in embryo development prior to uterine implantation in the biopsied and control groups, which is consistent with results found in humans. However, following implantation, successful births from biopsied embryos were significantly lower than in...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...